CONSIDER VYEPTI FOR YOUR PATIENTS LIKE CAROL
Every patient who suffers from migraine has a unique set of challenges to navigate.
This website is intended for US healthcare professionals only.
VYEPTI permanent J-code (J3032) is now available. Learn more
FIND A VYEPTI-READY INFUSION CENTER IN YOUR AREA
You are about to leave the VYEPTI website for healthcare professionals
VYEPTI Dosing and Administration Video Coming Soon
Episodic migraine patient profile*
*Episodic migraine was defined as 4 to 14 headache days per month, of which ≥4 were migraine days.1 One month was defined as 28 consecutive days.2
In patients like Carol, which factor would most likely lead you to consider updating her current treatment regimen?
Here’s how others responded:
Compliance issues
Increased use of acute medications
Busy, working mother
Fear of self-injection
Meet Carol†‡
†Fictitious patient case.
PATIENT INFORMATION
Age: 35 years old
Sex: Female
Diagnosis: Episodic migraine, 17 years
Mean migraine days per month: 11
Comorbidities: Obesity
TREATMENT HISTORY
Migraine medication use
- Currently on an oral antiepileptic for migraine prevention
- Additionally, treating migraine acutely with prescription and over-the-counter oral medications
Concomitant medication use
- Presently on birth control (IUD)
FACTORS FOR CONSIDERATION
- Compliance issues with current preventive treatment due to side effects
- Acute medication use is increasing
- Her migraine attacks typically last longer than 12 hours
- Consistently sees her neurologist on a quarterly basis
- Busy, working mother with two young children—fears she is neglecting her work and family obligations
- Increased absenteeism and presenteeism
- Afraid of self-injection
‡This patient profile may represent some of the healthcare challenges that could be encountered during typical clinical practice. Symptoms and responses to any treatment may vary. As always, use your clinical judgement.
Consider VYEPTI for your patients like Carol
With one 30-minute IV infusion every 12 weeks, VYEPTI has the potential to help some patients overcome challenges associated with migraine.1
Learn more about VYEPTI in episodic migraine
IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications
VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.
INDICATION
VYEPTI is indicated for the preventive treatment of migraine in adults.
Warnings and Precautions
Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.
Adverse Reactions
The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.
For more information, please see the Prescribing Information and Patient Information.
IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications
VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.
INDICATION
VYEPTI is indicated for the preventive treatment of migraine in adults.
Warnings and Precautions
Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.
Adverse Reactions
The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.
For more information, please see the Prescribing Information and Patient Information.
References:
- VYEPTI (eptinezumab-jjmr) [package insert]. Bothell, WA: Lundbeck Seattle BioPharmaceuticals, Inc.
- Data on file. Bothell, WA: Lundbeck Seattle BioPharmaceuticals, Inc.
© 2021 Lundbeck. All rights reserved. VYEPTI, VYEPTI CONNECT, and VYEPTI GO are trademarks of Lundbeck Seattle BioPharmaceuticals, Inc. EPT-B-100032v4
This website is intended for US healthcare professionals only.
